Diligence memo · auto-generated · as of July 2, 2026
Enhanced Fusion Technologies L.L.C.
Enhanced Fusion Technologies L.L.C. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Enhanced Fusion Technologies L.L.C. operates in Biotechnology, based in VIENNA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Enhanced Fusion Technologies L.L.C. has raised $480K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $480K on 2025-07-28.
Most recent recorded round closed around 2025-07-28.
Valuation (modeled)modeled
Provath models Enhanced Fusion Technologies L.L.C. at approximately $1.1M (range $256K–$2.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.19× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 11 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 10% of Biotechnology peers (4293 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.